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Heart  failure  with
reduced  ejection
fraction
Abstract  Renin-angiotensin-aldosterone  system  (RAAS)  inhibitors  are  a  cornerstone  in  the
treatment of  heart  failure  with  reduced  ejection  fraction  (HFrEF).  Sacubitril/valsartan  mod-
ulates the  neurohormonal  axis  by  inhibiting  both  angiotensin  receptors  and  neprilysin,  and
improves neurohormonal  balance  more  than  blocking  the  RAAS  alone.
The PARADIGM-HF  trial  validated  this  new  treatment  option  for  patients  with  HFrEF.  Sacu-
bitril/valsartan  was  also  more  effective  than  enalapril  in  slowing  disease  progression  by
decreasing  the  risk  of  worsening  heart  failure  requiring  hospitalization  or  emergency  admis-
sion and  the  need  for  intensified  therapy,  heart  failure  devices  or  cardiac  transplantation.  More
than 70%  of  patients  included  in  PARADIGM-HF  were  in  NYHA  class  II,  and  overall,  the  results
indicate  that  sacubitril/valsartan  should  be  started  in  the  earliest  symptomatic  stages  of  the
disease.
As PARADIGM-HF  has  excellent  robustness  for  a  cardiovascular  trial,  sacubitril/valsartan  has
been included  as  a  new  treatment  option  with  a  strong  level  of  recommendation  in  the  main
international  guidelines.
This  expert  task  force  proposes  a  practical  guide  to  the  use  of  this  new  drug  that  has  been
endorsed by  the  Working  Group  on  Heart  Failure  of  the  Portuguese  Society  of  Cardiology.sa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  All  rights© 2019  Sociedade  Portugue
reserved.∗ Corresponding author.
E-mail address: mcandidafonseca@gmail.com (C. Fonseca).
https://doi.org/10.1016/j.repc.2018.10.008
0870-2551/© 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.






com  fração  de  ejeção
reduzida
Sacubitril/valsartan:  um  guia  prático
Resumo  Os  inibidores  do  sistema  renina-angiotensina-aldosterona  são  uma  das  pedras
basilares no  tratamento  da  insuficiência  cardíaca  com  fração  de  ejeção  reduzida.  O  sacubi-
tril/valsartan  promove  a  modulação  neuro-hormonal,  bloqueando  os  recetores  da  angiotensina
e inibindo  a  neprilisina,  e  produz  um  maior  equilíbrio  neuro-hormonal,  mais  do  que  o  blo-
queio do  sistema  renina-angiotensina-aldosterona  isoladamente.  O  estudo  PARADIGM-HF  validou
essa nova  opção  para  o  tratamento  de  doentes  com  insuficiência  cardíaca  e  fração de  ejeção
reduzida, em  alternativa  ao  IECA/ARA.
O sacubitril/valsartan  demonstrou  ser  mais  eficaz  do  que  o  enalapril  em  retardar  a
progressão  da  doença,  diminuindo  o  risco  de  agravamento  da  insuficiência  cardíaca  através
da diminuição  da  necessidade  de  hospitalização  e  da  menor  necessidade  de  intensificação  ter-
apêutica, dispositivos  ou  transplante  cardíaco.  Mais  de  70%  dos  doentes  incluídos  no  estudo
PARADIGM-HF  estavam  em  classe  II  da  NYHA,  suportando  a  utilização  do  sacubitril/valsartan
precocemente  após  o  início  dos  sintomas.
Como  o  estudo  PARADIGM-HF  apresentou  uma  robustez  sem  precedentes  para  um  estudo
cardiovascular,  o  sacubitril/valsartan  foi  incluído  como  uma  nova  opção  de  tratamento  nas
Recomendações internacionais  mais  relevantes,  com  um  elevado  nível  de  evidência  (I-B).
Este grupo  de  peritos  em  Insuficiência  Cardíaca  vem  propor  uma  orientação  prática  para  a
utilização deste  novo  fármaco,  subscrita  pelo  Grupo  de  Estudos  de  Insuficiência  Cardíaca  da
Sociedade  Portuguesa  de  Cardiologia.



























































Most  of  the  clinical  evidence  of  benefit  comes  fromntroduction
acubitril/valsartan  modulates  the  neurohormonal  axis  by
nhibiting  both  angiotensin  receptors  and  neprilysin,  and
mproves  neurohormonal  balance  more  than  blocking  the
enin-angiotensin-aldosterone  system  (RAAS)  alone.1 The
rospective  comparison  of  ARNi  with  ACEi  to  Determine
mpact  on  Global  Mortality  and  Morbidity  in  Heart  Failure
PARADIGM-HF)  trial  validated  this  new  treatment  option
or  patients  with  heart  failure  (HF)  with  reduced  ejection
raction  (HFrEF).2
In  the  PARADIGM-HF  trial,  patients  receiving  sacubi-
ril/valsartan  had  a  20%  lower  risk  of  cardiovascular  death
nd  lived  up  to  two  years  longer  than  those  receiving
nalapril.3,4 This  impact  on  cardiovascular  death  was  driven
y  a  similar  decrease  in  the  risk  of  sudden  death  and
eath  due  to  worsening  HF,  unlike  what  was  observed  with
ngiotensin-converting  enzyme  inhibitors  (ACEIs),  which
howed  no  impact  on  sudden  death.5 Sacubitril/valsartan
as  also  more  effective  than  enalapril  in  slowing  disease
rogression,  by  decreasing  the  risk  of  worsening  HF  requir-
ng  hospitalization  or  emergency  admission  and  the  need  for
ntensification  of  therapy,  HF  devices  or  cardiac  transplanta-
ion.  Overall,  the  results  indicate  that  sacubitril/valsartan
hould  be  started  in  the  earliest  symptomatic  stages  of  the
isease.3,6
As  PARADIGM-HF  has  excellent  robustness  for  a  car-
iovascular  trial,  sacubitril/valsartan  has  been  included
s  a  new  treatment  option  with  a  strong  level  of  rec-
mmendation  (class  I,  level  of  evidence  B)  in  the  main
nternational  guidelines.7--9 The  Web  Addenda  of  the  2016
uropean  Society  of  Cardiology  (ESC)  guidelines  provide
ractical  guidance  on  the  use  of  certain  HF  drugs,  but  not  on
p
c
acubitril/valsartan.  The  authors  propose  to  provide  similar
uidance  for  sacubitril/valsartan  in  the  current  document.
uidance
acubitril/valsartan,  an  angiotensin  receptor-neprilysin
nhibitor  (ARNI),  is  indicated  in  adult  patients  for  the  treat-
ent  of  symptomatic  chronic  HFrEF  to  further  reduce  the
isk  of  HF  hospitalization  and  cardiovascular  death.10 When
nitiating  sacubitril/valsartan,  ACEIs,  angiotensin  receptor
lockers  (ARBs),  and  direct  renin  inhibitors  (if  prescribed)
ust  be  discontinued.  Moreover,  any  patient  pretreated
ith  an  ACEI  should  undergo  a  36-hour  washout  period  prior
o  initiating  sacubitril/valsartan,  in  order  to  avoid  increased
isk  of  angioedema.  This  is  not  necessary  when  switching
rom  an  ARB  to  an  ARNI.11,12
When  initiating  sacubitril/valsartan,  it  is  important  to
nsure  that  blood  pressure  (BP)  is  adequate  (systolic  BP
100  mmHg)  and  potassium  level  is  <5.5  mmol/l.  Esti-
ated  glomerular  filtration  rate  should  be  ≥30  ml/min/1.73
2; below  this  value,  sacubitril/valsartan  must  be  used
ith  caution,  and  is  not  recommended  in  end-stage  renal
isease  and  in  patients  undergoing  hemodialysis.  Sacu-
itril/valsartan  should  not  be  used  in  the  presence  of
rimary  or  severe  hepatic  impairment  (Child-Pugh  class  C);
rimary  hepatic  impairment  should  be  suspected  in  the
bsence  of  other  signs  of  congestion.  However,  if  hep-
tic  enzymes  are  elevated  due  to  hepatic  congestion,  this
hould  not  be  considered  a  contraindication  for  sacubitril/
alsartan.atients  in  New  York  Heart  Association  (NYHA)  functional
lass  II/III  (70%  of  patients  included  in  PARADIGM-HF  were
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Table  1  Practical  guidance  on  the  use  of  sacubitril/valsartan  in  patients  with  heart  failure  with  reduced  ejection  fraction.
Why?  Ref.
To  improve  the  natural  course  of  the  disease  by  further  reducing  the  risk  of  HF
hospitalization  and  mortality
8
In  whom  and  when?
Indications  8,12,15
1.  Adult  patients  with  heart  failure  and  reduced  ejection  fraction  (LVEF  <40%)
2. Replacement  of  ACEI/ARB  in  patients  who  remain  in  NYHA  class  II-IV  despite
treatment  with  an  ACEI/ARB,  a  beta-blocker  and  a  MRA
3. Patients  should  have  SBP  ≥100  mmHg  and  serum  potassium  level  <5.5  mmol/l
Contraindications
1. Concomitant  use  with  ACEI  or  ARBa
2.  Concomitant  use  with  aliskiren-containing  medicines  in  patients  with  diabetes  or
with renal  impairment  (eGFR  <60  ml/min/1.73  m2)a
3.  Previous  history  of  angioedema
4.  Severe  hepatic  impairment,  biliary  cirrhosis  or  cholestasis  (Child-Pugh  class  C)b
Cautions  during  treatment  and  reasons  to  seek  specialist  advice 10
1.  Symptomatic  hypotension
2.  Impaired/worsening  renal  functionc
3.  Hyperkalemia  (serum  potassium  ≥5.5  mmol/l)
What dose?
Population Initial  dose Titration
Patients  on  moderate  or  high-dose  ACEI
Equivalent  of  enalapril  ≥10  mg  twice  daily
49/51  mg  twice
Daily  (if  previous  ACEI,  ensure  36h
washout  periodd)
Double  the  dose  at
2-4  weeks
10,12
Patients  on  moderate  or  high-dose  ARB
Equivalent  of  valsartan  ≥80  mg  twice  daily
Patients  on  low-dose  ACEI
Equivalent  of  <10  mg  of  enalapril  twice
daily
24/26  mg  twice
daily  (if  previous  ACEI,  ensure
36-hour  washout  periodd)
Double  the  dose
every  3-4  weeks
Patients on  low-dose  ARB
Equivalent  of  valsartan  ≤80  mg  twice  daily
ACEI/ARB-naïve  patients
Patients  with  severe  renal  impairment
(eGFR  <30  ml/min/1.73  m2)
Patients  with  moderate  hepatic  impairment
(Child-Pugh  class  B)
Elderly  patients  (age  ≥75  years)
How  to  use?
If  natrituretic  peptides  are  assessed  for  monitoring  HF  decompensation,  NT-proBNP  should  be  used,  not  BNP  8,10
Monitor  blood  pressure  regularly
Check  renal  function
Monitor  serum  potassium  levels
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Table  1  (Continued  )
Trouble-shooting
Hypotension  8,10
If  symptomatic  hypotension  occurs,  considere:
1. adjustment  of  doses  of  concomitant  medication
2. temporary  down-titration  of  sacubitril/valsartan
3. discontinuation  of  sacubitril/valsartan
Worsening  renal  function
If clinically  significant  deterioration  of  renal  function  occurs,  down-titration  should  be  considered
Hyperkalemia
If hyperkalemia  occurs,  considere:
1. adjustment  of  concomitant  potassium-sparing  drugs
2. temporary  down-titration  of  sacubitril/valsartan
3. discontinuation  of  sacubitril/valsartan
If serum  potassium  level  is  ≥5.5  mmol/l  discontinuation  is  recommended
Angioedema
If angioedema  occurs,  sacubitril/valsartan  should  be  immediately  discontinued  and  must  not  be  reintroduced.
What to  discuss  with  the  patient
Involve  patients  in  the  decision-making  process
Ensure  patients  understand  the  beneficial  impact  of  the  drug  on  prognosis  to  improve  long-term  adherence  to  therapy
Inform patients  about  potential  side  effects:  dizziness  and  hypotension  angioedema,  itching  and  rash
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor-neprilysin inhibitor; eGFR:
estimated glomerular filtration rate; AST/ALT: aspartate transaminase/alanine transaminase ratio; LVEF: left ventricular ejection frac-
tion; NT-proBNP: N-type pro-B-type natriuretic peptide; NYHA: New York Heart Association; RAAS: renin-angiotensin-aldosterone system;
SBP: systolic blood pressure; SmPC: Summary of Product Characteristics.
a Dual RAAS inhibition is not recommended.
b Limited clinical experience with Child-Pugh class C patients or AST/ALT levels two times normal
c Decline in renal function is defined as 0.3 mg/dl increase in serum creatinine. However, if the patient is clinically stable, consider
maintaining the dose of sacubitril/valsartan and assess renal function after 2 weeks.
d Same period should be considered if patients switch from ARNI to ACEI.








































n  NYHA  class  II).  Therefore,  sacubitril/valsartan  should  be
nitiated  in  the  early  stages  of  the  disease.
The  optimal  timing  for  switching  from  ACEIs/ARBs  to
acubitril/valsartan  has  continued  to  evolve  in  the  light
f  new  clinical  evidence  and  experience.  The  2016  ESC
uidelines  on  HF  recommend  switching  in  symptomatic
atients  after  titration  of  an  ACEI/ARB,  a  beta-blocker
nd  a  mineralocorticoid  receptor  antagonist  (MRA)  to  max-
mally  tolerated  evidence-based  doses.8 The  most  recent
merican  College  of  Cardiology/American  Heart  Associa-
ion  (ACC/AHA)  expert  consensus  document9 suggests  that
witching  can  be  performed  earlier,  regardless  of  maximum
olerated  doses  of  ACEIs/ARBs  and/or  introduction  of  an
RA.  Use  of  an  MRA,  although  also  recommended  to  improve
utcomes,  is  not  considered  mandatory  prior  to  changing  a
atient  to  an  ARNI.9,13
Sacubitril/valsartan  should  be  initiated  according  to  the
atient’s  profile  and  the  background  RAAS  inhibition  ther-
py.  If  tolerated,  the  target  dose  is  97/103  mg  twice  daily.
When  monitoring  a  patient  newly  treated  with  sacubi-
ril/valsartan,  it  is  important  to  measure  BP  regularly  and
o  reassess  the  indication  for  all  concomitant  medications
hat  could  reduce  BP,  such  as  diuretics  or  antihypertensive





Renal  function  and  serum  potassium  should  be  moni-
ored  on  starting  sacubitril/valsartan.  In  the  PARADIGM-HF
rial,  patients  receiving  sacubitril/valsartan  were  less  likely
o  experience  renal  impairment  and  hyperkalemia  requir-
ng  discontinuation  of  the  study  medication  than  those
n  enalapril.3 If  a  patient  experiences  clinically  signifi-
ant  hyperkalemia,  the  concomitant  medications  should  be
djusted.  If  serum  potassium  remains  ≥5.5  mmol/l,  dis-
ontinuation  of  sacubitril/valsartan  should  be  considered.
ARADIGM-HF  demonstrated  that,  compared  with  enalapril,
acubitril/valsartan  enhanced  the  possibility  of  using  MRAs
afely,  due  to  a  lower  incidence  of  hyperkalemia.14
onitoring  of  renal  function  and  serum  potassium  is  rec-
mmended  between  two  and  four  weeks  after  starting
he  therapy  and  at  each  dose  titration  (until  maximum
olerated  dose),  at  three  months,  and  every  six  months
hereafter.
Patients  on  sacubitril/valsartan  should  be  monitored
or  N-terminal  pro-B-type  natriuretic  peptide  (NT-proBNP)
nstead  of  B-type  natriuretic  peptide  (BNP)  levels.  BNP  is substrate  for  neprilysin,  the  enzyme  that  is  inhibited  by
acubitril.  Therefore,  an  increase  in  BNP  levels  cannot  be
nterpreted  as  a  biomarker  of  HF  decompensation  or  used







Sacubitril/valsartan:  A  practical  guide  
When  sacubitril/valsartan  is  being  considered,  patients
should  be  involved  and  should  play  a  central  role  in  the
decision-making  process.  They  should  understand  the  drug’s
indications  and  dosing,  recognize  the  common  side  effects,
and  know  when  to  inform  a  healthcare  professional.  Further-
more,  patients  should  be  aware  of  the  benefit  of  taking  the
drug  as  prescribed  and  its  impact  on  disease  progression,  in
order  to  improve  long-term  adherence  to  therapy  (Table  1).8
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